Navigation Links
Amylin Pharmaceuticals Reports 2010 Financial Results
Date:1/26/2011

d-on therapy to basal insulin, with or without metformin and/or a TZD in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.
  • Lilly received approval of BYETTA in Canada for the treatment of adults with type 2 diabetes for use as a combination therapy with metformin and/or a sulfonylurea to improve blood sugar control in adults with type 2 diabetes who have not achieved adequate glycemic control on maximally tolerated doses of these oral therapies, in addition to diet and exercise.

  • Lipodystrophy Program

  • Submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the FDA for the use of metreleptin to treat diabetes and/or hypertriglyceridemia in patients with rare forms of lipodystrophy. The Company plans to submit the chemistry, manufacturing and controls (CMC) section of the BLA by the end of 2011, which will complete the submission.

  • Corporate

  • Announced research collaboration agreement with the Juvenile Diabetes Research Foundation to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes.

  • Quarter Ended December 31, 2010Net product sales of $162.3 million for the quarter ended December 31, 2010 include U.S. sales of $136.4 million for BYETTA and $25.9 million for SYMLIN® (pramlintide acetate) injection. This compares to net product sales of $184.3 million, consisting of $163.7 million for BYETTA sales in the U.S. and $20.6 million for SYMLIN for the same period in 2009.

    Revenue under collaborative agreements was $11.9 million for the quarter ended December 31, 2010, compared to $1.3 million for the same period in 2009. In 2010, revenues under collaborative agreements consist of a $10.0 million milestone payment earned upon Lilly's December 2010 launch o
    '/>"/>

    SOURCE Amylin Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Amylin Pharmaceuticals to Webcast Year-End Financial Results
    2. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
    3. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
    4. Amylin Pharmaceuticals Reports Third Quarter Financial Results
    5. Amylin Pharmaceuticals to Present at the 2010 Credit Suisse Healthcare Conference
    6. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
    7. Amylin Pharmaceuticals to Webcast Third Quarter Results
    8. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
    9. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
    10. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
    11. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... 2014 Creekridge Capital, an independent vendor-focused ... vendors so far in 2014 to their portfolio ... are from both the healthcare and technology industries. ... well-known multi-national companies. Each of these new vendors ... products including: standard leasing products, subscription solutions, a ...
    (Date:7/23/2014)... YORK , July 23, 2014 ... Beach, Fla. , is an emerging player ... diagnostic systems for bio-threat detection and rapid medical ... called M-BAND (Microfluidic Bio-agent Autonomous Networked Detector), was ... Homeland Security ("DHS") Science & Technology directorate, and ...
    (Date:7/23/2014)... MEETING, Pa. , July 23, 2014 ... INO) today announced successful results from its ... VGX-3100 in women with biopsy-proven cervical intraepithelial ... (HPV) types 16 or 18. Treatment with ... regression of CIN2/3 to CIN1 or no ...
    Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5
    (Date:7/23/2014)... News) -- Painful or itchy skin lesions could be ... "Patients sometimes have multiple lesions that are suspicious looking, ... high concerns for non-melanoma skin cancers," study author Dr. ... of Medicine, said in a Temple University Health System ... of 268 patients who were confirmed to have skin ...
    (Date:7/23/2014)... Agricultural and Forestry University in Shaanxi province, and the ... agreement that lays the groundwork for establishing the Sino-U.S. ... The signing ceremony was held in the city of ... the U.S. Department of Agriculture and China,s Ministry of ... event for UC Davis and for our World Food ...
    (Date:7/23/2014)... 2014 The American Telemedicine Association ... twentieth annual meeting and tradeshow focused exclusively on ... attract over 5,000 attendees and more than 250 ... 3-5, 2015, in Los Angeles. , ATA’s annual ... professionals from researchers, clinicians, hospital and university administrators, ...
    (Date:7/23/2014)... 23, 2014 Bodybuilding.com, the Internet’s most-visited ... of nutritional supplements, has officially opened the polls for ... , the fastest growing sports nutrition company, is up ... of the Year, Best Tasting Protein of the Year- ... of the year - Whey-HD™, Pre-workout Supplement of the ...
    (Date:7/23/2014)... The voice on the recording was low and calm as the ... infected with the human immunodeficiency virus (HIV) that causes AIDS: “My ... know I was on the floor flat on my face boohooing, ... the recording ended less than 10 minutes later. “Don’t feel like ... it is just God setting you up for something greater,” the ...
    Breaking Medicine News(10 mins):Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 3Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3
    ... , Transplant surgeons at Johns Hopkins who have reviewed the ... that it is not simply racial differences, but rather flaws ... and education levels, in addition to biological factors, that are ... in African Americans. In a report on the review ...
    ... ... compensation costs , ... Oak Brook, IL (Vocus) May 31, 2010 -- AthletiCo Physical and Occupational Therapy ... OTR/L, to manage its Ergonomics and Job Analysis Program. Harris’s role as the ...
    ... urological problems, studies show , MONDAY, May 31 (HealthDay ... start exercising and steer clear of smoking, new research ... urinary health in women and sexual health in men. ... Finnish women, aged 18 to 79, about smoking and ...
    ... Medical Association Journal ) found a 68% increase in the ... link only) http://www.cmaj.ca/embargo/cmaj091208.pdf . Antidepressants are widely ... use them at some point during the first trimester. Discontinuing ... mother and baby at risk. Most previous studies ...
    ... illnesses kill more females than males, organizers say ... cancer death rates for women are generally on ... fatalities are rising, the American Lung Association (ALA) ... every year from tobacco-related illness, the ALA estimates. ...
    ... ... ... Those seeking to obtain ultimate health should take a page from author Fay Julius-Williams’ book, ... previous years and now walking in health, the author penned the new title in order ...
    Cached Medicine News:Health News:Lack of private insurance contribute to higher deaths among black heart transplant patients 2Health News:Lack of private insurance contribute to higher deaths among black heart transplant patients 3Health News:Lack of private insurance contribute to higher deaths among black heart transplant patients 4Health News:AthletiCo Physical Therapy Enhances Work Rehabilitation Program by Offering Ergonomics and Job Analysis 2Health News:AthletiCo Physical Therapy Enhances Work Rehabilitation Program by Offering Ergonomics and Job Analysis 3Health News:Antidepressants in pregnancy increase risk of miscarriage 2Health News:Women Smokers Targeted on 'World No Tobacco Day' 2Health News:Obtain Ultimate Health from Tips in New Xulon Press Title 2
    Small curved rounded blade. Flat serrated handle with polished finish....
    For use with E0828 needle and gouge set and E0828 C handle. Triangular shape curved 5.0 mm blade. Polished finish. Most popular size or model....
    Set consists of one each:E0824 A replacement burr set. E0824 B handle....
    5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
    Medicine Products: